Compare AST SpaceMobile Inc (ASTS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AST SpaceMobile Inc vs 10X Genomics Inc — how do they compare? AST SpaceMobile Inc trades at $72.25 (market cap $21.90B), while 10X Genomics Inc trades at $42.5 (market cap $5.43B). The key difference: AST SpaceMobile Inc is far larger — about 4× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.
| ASTS | TXG | |
|---|---|---|
Market Cap | $21.90B | $5.43B |
Sector | Media | Health |
52-Week High | $133.09 | $43.10 |
52-Week Low | $36.91 | $11.34 |
Enterprise Value | $21.87B | $4.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASTS trades at $73.32, down 0.76% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported revenue of $70.92 million in 2025 but sustained a net loss of $341.94 million, missing earnings expectations for three consecutive quarters. Recent news highlights potential in defense communications via satellite technology, though competition with SpaceX remains a focal point.
The outlook is speculative with high execution risk; analyst consensus is divided with a $90.33 price target. Investment opportunity hinges on successful satellite deployment and partnership execution, but persistent losses and intense competition pose significant downside risks for shareholders.
TXG trades at $42.73, down 0.86% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth and beat EPS estimates, with net losses narrowing significantly from -$166M in 2022 to -$44M in 2025. Recent collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics highlight strategic expansion in diagnostics and multiomics capabilities.
Outlook remains cautiously optimistic as improving margins and cash flow support growth, but high valuation multiples and persistent net losses pose risks. Analyst consensus is mixed with a $35.14 price target below current levels, suggesting limited near-term upside despite positive operational trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
